GILOTRIF®

Drug Information Related Patent

Hold Company

BOEHRINGER INGELHEIM

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE

Indication

GILOTRIF® is indicated for EGFR mutation-positive, metastatic non-small cell lung cancer as well as metastatic squamous NSCLC.

Use

Instructions for Use

API

AFATINIB DIMALEATE

API Structure

We Supply

AFATINIB DIMALEATE

Note:

Facility GMP
USMF/ASMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
10004743	2030/7/5
10004743*PED	2031/1/5
8426586	2029/10/10
8426586*PED	2030/4/10
8545884	2029/12/19
8545884*PED	2030/6/19
9539258	2026/11/9
9539258*PED	2027/5/9
RE43431	2026/1/13
RE43431*PED	2026/7/13

API Patent

Patent No	Expiration Date
8426586	2029/10/10
8426586*PED	2030/4/10
RE43431	2026/1/13
RE43431*PED	2026/7/13

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION